Headquartered in Berkeley Heights, NJ Fiscal year ends December NASDAQ: TNXP tonixpharma.com
Tonix Pharmaceuticals is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders, infectious diseases, and immunology conditions with high unmet medical needs.
Its flagship product is TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), a centrally acting, non-opioid analgesic for fibromyalgia in adults. TONMYA was internally developed, launched in November 2025, and is described by the company as the first FDA-approved fibromyalgia treatment in more than 15 years. Tonix sells it through a sales force of about 150 representatives and a digital pharmacy channel. Coverage reaches approximately 166 million U.S. covered lives across commercial, managed Medicare, and Medicaid plans.
The company's CNS commercial infrastructure also supports two acute migraine products: Zembrace SymTouch (sumatriptan injection 3 mg) and Tosymra (sumatriptan nasal spray 10 mg).
The pipeline includes:
- **TNX-102 SL:** in Phase 2 development for major depressive disorder (the Tonix-led HORIZON study) and acute stress disorder/reaction (investigator-initiated).
- **TNX-4800:** a long-acting anti-OspA monoclonal antibody for seasonal Lyme disease prevention in the U.S.
- **TNX-1500 (mosdaprubart):** a third-generation anti-CD40L monoclonal antibody for preventing kidney transplant rejection and treating autoimmune diseases.
TONMYA currently faces a Paragraph IV generic challenge from Dr. Reddy's Laboratories. Updated
A new fibromyalgia drug just reached tens of millions of Medicare members, and patients are already assuming their costs are settled. One document their insurer controls will tell a very different story…
Gerelyn Terzo These nine stocks made big moves, up or down, after the close on Monday, July 20, 2020.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders, infectious diseases, and immunology conditions with high unmet medical needs.
The Wall Street consensus 12-month price target for TNXP is $34.00.
